Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21864002 | 0.90 | USP5 (0.39) | EGLN2EGLN1EGLN3PTGDR2P2RX7 | |
| SCHEMBL21660803 | 0.88 | KDM4E (0.44) | HTTTP53L3MBTL1P2RX7RAB9A | |
| SCHEMBL21660817 | 0.85 | CHRM4 (0.45) | EGLN2EGLN1EGLN3PTGDR2ALDH1A1 | |
| SCHEMBL21660770 | 0.82 | EGLN1 (0.43) | EGLN1TP53USP5ALDH1A1 | |
| SCHEMBL21660807 | 0.81 | HTT (0.43) | HTTTP53GAAL3MBTL1NPC1 | |
| SCHEMBL21864011 | 0.81 | PSMB5 (0.43) | TP53L3MBTL1P2RX7ACKR3 | |
| SCHEMBL21864004 | 0.80 | ALDH1A1 (0.41) | HTTTP53P2RX7RAB9AALDH1A1 | |
| SCHEMBL21864051 | 0.78 | PSMB5 (0.57) | — | |
| SCHEMBL21661134 | 0.78 | CHRM2 (0.38) | EGLN1USP5 | |
| SCHEMBL21660809 | 0.76 | GAA (0.42) | HTTTP53GAAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831834-A1 | BORATE OF AZETIDINE DERIVATIVE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210163507-A1 | BORATE OF AZETIDINE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-11014943-B2 | Azetidine derivative | CHIA TAI TIANQING PHARMACEUTICAL GROUP GO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2020025037-A1 | BORATE OF AZETIDINE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014943-B2 | Azetidine derivative | BCL9, MCL1, BCL9L | HTT 1097/4885EGLN2 3442/4885EGLN1 4319/4885 |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | BCL9, MCL1, BCL9L | HTT 1097/4885EGLN2 3442/4885EGLN1 4319/4885 |
| US-20210163507-A1 | BORATE OF AZETIDINE DERIVATIVE | BCL9, BCL6, BCL6B | HTT 640/4885EGLN2 2920/4885EGLN1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.